Skip to main content
. 2022 Mar 8;14:1759720X221080377. doi: 10.1177/1759720X221080377

Table 1.

Baseline characteristics of studies included in the meta-analysis.

Studies Type Group Target Intervention Treatment period N Female (%) Age (y) Joint Duration since diagnosis (y)
Chevalier et al. 38 RCT Anakinra 50 mg IL-1 IA; once 1 day 34 50.0 63.3 Knee 8.1
Anakinra 150 mg 67 68.7 62.6 5.2
Placebo 69 63.8 62.2 6.0
Lane et al. 21 RCT Tanezumab 10 µg/kg NGF IV q8 wk; twice 16 weeks 74 66.2 58.3 Knee NA
Tanezumab 25 µg/kg 74 67.6 59.9 NA
Tanezumab 50 µg/kg 74 50.0 60.4 NA
Tanezumab 100 µg/kg 74 59.5 57.1 NA
Tanezumab 200 µg/kg 74 54.1 58.4 NA
Placebo 74 56.8 58.1 NA
Nagashima et al. 39 RCT Tanezumab 10 µg/kg NGF IV; once 1 day 15 66.7 59.3 Knee 4.5
Tanezumab 25 µg/kg 15 53.3 57.3 7.3
Tanezumab 50 µg/kg 15 73.3 60.7 4.2
Tanezumab 100 µg/kg 16 75.0 58.1 3.8
Tanezumab 200 µg/kg 6 83.3 60.0 5.4
Placebo 16 68.8 59.4 7.9
Cohen(A) et al. 23 RCT AMG108 100 mg IV IL-1 IV or SC q4 wk; 12 weeks 12 91.7 61.1 Knee 6.9
AMG108 300 mg IV 3 times 12 58.3 62.8 10.2
AMG108 300 mg SC 12 41.7 59.6 6.6
AMG108 75 mg SC 12 75.0 62.3 10.0
Placebo 16 62.5 60.8 9.6
Cohen(B) et al. 23 RCT AMG108 300 mg IL-1 SC q4 wk; 3 times 12 weeks 80 67.5 61.3 Knee 6.1
Placebo 80 67.5 60.1 6.1
Brown et al. 22 RCT Tanezumab 2.5 mg NGF IV q8 wk; 3 times 24 weeks 172 54.7 60.8 Knee 7.3
Tanezumab 5 mg 172 58.7 62.1 7.5
Tanezumab 10 mg 174 60.9 61.4 9.5
Placebo 172 69.2 62.2 8.2
Verbruggen et al. 24 RCT Adalimumab 40 mg TNF-α SC q2 wk; 26 times 52 weeks 30 86.7 61.9 Hand 9.6
Placebo 30 83.3 60.7 14.4
NCT01160822(A) et al. 40 RCT Canakinumab 150 mg IL-1 IA; once 1 day 6 50.0 58.3 Knee NA
Canakinumab 300 mg 7 57.1 61.0 NA
Canakinumab 600 mg 6 33.3 64.2 NA
Placebo 5 40.0 57.8 NA
NCT01160822(B) et al. 40 RCT Canakinumab 600 mg IL-1 IA; once 1 day 45 68.9 61.4 Knee NA
Naproxen 500 mg 53 64.2 62.2 NA
Placebo 47 66.0 60.3 NA
Spierings et al. 41 RCT Tanezumab 5 mg NGF IV q8 wk; twice 16 weeks 161 59.6 57.8 Knee 7.6
Tanezumab 10 mg 150 62.7 57.0 or 7.5
Oxycodone 10–40 mg 158 62.7 57.6 Hip 6.2
Placebo 141 65.2 57.2 7.4
Brown et al. 42 RCT Tanezumab 2.5 mg NGF IV q8 wk; 3 times 24 weeks 155 65.2 62.4 Hip 6.0
Tanezumab 5 mg 154 59.7 61.8 6.3
Tanezumab 10 mg 157 56.1 63.3 5.6
Placebo 155 66.5 61.9 5.6
Sanga et al. 43 RCT Fulranumab 1 mg q4 wk NGF SC q4 wk or q8 wk; 4 times or 2 times 12 weeks 77 58.4 61.2 Knee NA
Fulranumab 3 mg q4 wk 79 58.2 60.8 or NA
Fulranumab 3 mg q8 wk 76 59.2 60.5 Hip NA
Fulranumab 6 mg q8 wk 78 60.3 60.7 NA
Fulranumab 10 mg q8 wk 78 53.8 61.4 NA
Placebo 78 55.1 61.3 NA
Ekman(A) et al. 36 RCT Tanezumab 5 mg NGF IV q8 wk; twice 16 weeks 206 59.2 61.1 Knee 7.9
Tanezumab 10 mg 208 61.5 61.1 8.5
Naproxen 500 mg 206 62.6 61.4 7.2
Placebo 208 57.7 60.9 9.0
Ekman(B) et al. 36 RCT Tanezumab 5 mg NGF IV q8 wk; twice 16 weeks 211 65.1 60.1 Knee 6.4
Tanezumab 10 mg 209 63.5 59.8 or 6.8
Naproxen 500 mg 211 61.2 59.2 Hip 7.7
Placebo 209 64.5 60.3 6.3
Brown et al. 44 RCT Tanezumab 5 mg NGF IV q8 wk; 3 times 24 weeks 73 60.3 57.8 Knee NA
Tanezumab 10 mg 74 63.5 58.0 or NA
Placebo 72 54.2 56.3 Hip NA
Tiseo et al. 45 RCT Fasinumab 0.03 mg/kg NGF IV q8 wk; twice 16 weeks 53 60.4 59.0 Knee NA
Fasinumab 0.1 mg/kg 53 67.9 60.3 NA
Fasinumab 0.3 mg/kg 54 68.5 58.8 NA
Placebo 55 78.2 59.1 NA
Chevalier et al. 46 RCT Adalimumab 40 mg TNF-α SC q15 d; twice 1 month 41 87.8 62.8 Hand 13.5
Placebo 42 83.3 62.2 13.5
Gow et al. 47 RCT AMG403 3 mg NGF SC q4 wk; 4 times 16 weeks 6 33.3 53.0 Knee NA
AMG403 10 mg 6 50.0 48.7 NA
AMG403 20 mg 6 50.0 52.7 NA
Placebo 6 83.3 54.7 NA
Mayorga et al. 48 RCT Fulranumab 3 mg NGF SC q4 wk; 4 times 16 weeks 48 62.5 59.2 Knee NA
Fulranumab 9 mg 50 60.0 58.8 NA
Oxycodone 20–50 mg 50 50.0 58.6 NA
Placebo 48 52.1 60.9 NA
Wang et al. 49 RCT ABT981 0.3 mg/kg q2 wk IL-1 SC q2 wk or q4 wk; 8 weeks or 7 71.4 61.3 Knee NA
ABT981 1 mg/kg q2 wk 4 times or 3 times 12 weeks 7 71.4 62.6 NA
ABT981 3 mg/kg q2 wk 7 100 61.4 NA
Placebo q2 wk 6 83.3 60.0 NA
ABT981 3 mg/kg q4 wk 7 100 60.0 NA
Placebo q4 wk 2 100 55.0 NA
Birbara et al. 26 RCT Tanezumab 2.5 mg SC NGF SC or IV q8 wk; 16 weeks 74 64.9 61.0 Knee 7.3
Tanezumab 5 mg SC twice 63 57.1 60.3 9.1
Tanezumab 10 mg SC 86 62.8 58.2 8.7
Tanezumab 10 mg IV 84 57.1 59.6 8.2
Placebo 72 65.3 61.3 9.6
Walicke et al. 50 RCT Tanezumab 3 µg/kg NGF IV; once 1 day 4 100.0 47.3 Knee NA
Tanezumab 10 µg/kg 4 75.0 52.8 NA
Tanezumab 30 µg/kg 4 50.0 51.5 NA
Tanezumab 100 µg/kg 6 33.3 51.8 NA
Tanezumab 300 µg/kg 6 33.3 53.7 NA
Tanezumab 1000 µg/kg 6 66.7 52.8 NA
Placebo 12 75.0 49.8 NA
Aitken et al. 37 RCT Adalimumab 40 mg TNF-α SC q2 wk; 6 times 12 weeks 18 83.3 63.1 Hand NA
Placebo 25 72.0 61.2 NA
Kloppenburg et al. 51 RCT Etanercept 50/25mg TNF-α SC q1 wk; 52 times 1 year 45 82.2 59.4 Hand 6.2
Placebo 45 80.0 60.1 7.3
NCT01144143 et al. 52 RCT Infliximab 10 mg TNF-α IA; once 1 day 8 62.5 NA Knee NA
MP 80 mg 4 100 NA NA
Placebo 4 100 NA NA
Schnitzer et al. 53 RCT Tanezumab 2.5 mg NGF SC q8 wk; twice 16 weeks 231 62.8 60.9 Knee 6.4
Tanezumab 2.5/5 mg 233 64.8 61.2 or 7.2
Placebo 232 67.7 60.4 Hip 6.9
Kelly et al. 54 RCT Fulranumab 1 mg NGF SC q4 wk; 4 times 16 weeks 81 69.1 62.0 Knee NA
Fulranumab 3 mg 83 51.8 63.0 or NA
Placebo 81 65.4 64.4 Hip NA
Dakin et al. 55 RCT Fasinumab 1 mg NGF SC q4 wk; 4 times 16 weeks 85 69.4 60.7 Knee NA
Fasinumab 3 mg 84 64.3 60.7 or NA
Fasinumab 6 mg 85 60.0 60.1 Hip NA
Fasinumab 9 mg 84 64.3 61.5 NA
Placebo 83 65.1 60.1 NA
Kloppenburg et al. 56 RCT Lutikizumab 200 mg IL-1 SC q2 wk; 12 times 24 weeks 64 82.8 66.0 Hand 11.0
Placebo 67 86.6 66.0 11.0
Fleischmann et al. 57 RCT Lutikizumab 25 mg IL-1 SC q2 wk; 26 times 52 weeks 89 70.8 61.6 Knee 7.6
Lutikizumab 100 mg 85 62.4 60.2 7.9
Lutikizumab 200 mg 88 64.8 59.1 8.7
Placebo 85 61.2 59.5 7.9
Berenbaum et al. 58 RCT Tanezumab 2.5 mg TNF-α SC q8 wk; 3 times 24 weeks 283 70.0 65.2 Knee 6.0
Tanezumab 5 mg 284 68.0 65.2 or 6.7
Placebo 282 69.5 64.2 Hip 7.4

IA, intra-articular; IL-1, interleukin-1; IV, intravenous; MP, methylprednisolone; NA, data not available; NGF, nerve growth factor; RCT, randomized controlled trial; SC, subcutaneous; TNF-α, tumor necrosis factor-α.